The initial daily dose was 375 mg, which was then titrated once weekly to 500, 750 and 1,000 mg, as tolerated. The control group received placebo. All patients in each group still received their phosphate-binding medication as
standard treatment.
Results: At the 12th week, mean serum phosphorus of the treatment group significantly decreased from 7.13 +/- 1.09 mg/dL to 5.65 +/- 1.22 mg/dL (p<0.001). However, there was no statistically significant difference between the control and treatment groups. Nine out NVP-AUY922 of the 14 patients.(64.29%) in the treatment group achieved the K/DOQI serum phosphorus goal. Serum high-density lipoprotein cholesterol of patients in the treatment group increased by 30.22% from baseline (p=0.037). There were no significant changes in serum calcium or parathyroid hormone level in any of the patients. Hot flushes were observed in all patients of the treatment group. There were no significant changes in the fasting blood glucose level, uric BIBW2992 mw acid or liver function enzymes in any
of the patients.
Conclusions: Extended-release nicotinic acid is effective and safe in reducing serum phosphorus as an add-on standard therapy in hemodialysis patients.”
“Background: The population of gynaecological cancer survivors is growing, yet little is known about the effects of cancer and treatment on socioeconomic conditions well beyond the completion of therapy. The aim of this study was to investigate the socioeconomic conditions in long-term survivors of gynaecological cancer compared with a
representative group of women from the general population.
Material p38 protein kinase and methods: The study comprises women aged 32-75 residing in central part of Norway and who were treated as primary cases of gynaecological cancer at the University Hospital in Trondheim, Norway (n = 160), and a control group from the general population (n = 493). All analyses were done by chi(2) test and logistic regression.
Results: Gynaecological cancer survivors scored lower on a Socioeconomic Condition Index than the control group. They had on the average a complete remission period of 12 years. Compared with the control group, they were more often disabled (p < 0.01) and had lower annual household income (p < 0.01). No difference was detected between the groups in ability to pay bills. More cases than controls had experienced problems assigning personal insurance (p < 0.03).
Conclusion: Long-term gynaecological cancer survivors lived under poorer socioeconomic conditions, were more often disabled and had lower annual household income than the women in the control group, whereas no difference in ability to pay bills were found between the groups. In spite of poorer socioeconomic conditions, the gynaecological cancer survivors seem to adapt well to their financial situation. Copyright (C) 2009 John Wiley & Sons, Ltd.